PA
SUPN icon

Parallel Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Parallel Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08K Sell
21
-75
-78% -$3.82K ﹤0.01% 3531
2025
Q4 		$4.77K Buy
96
+73
+317% +$3.55K ﹤0.01% 2862
2025
Q3 		$1.1K Sell
23
-9
-28% -$362 ﹤0.01% 3198
2025
Q2 		$1.01K Buy
32
+20
+167% +$641 ﹤0.01% 3190
2025
Q1 		$393 Hold
12
– – ﹤0.01% 3274
2024
Q4 		$434 Hold
12
– – ﹤0.01% 3246
2024
Q3 		$374 Hold
12
– – ﹤0.01% 3223
2024
Q2 		$321 Hold
12
– – ﹤0.01% 3148
2024
Q1 		$409 Hold
12
– – ﹤0.01% 3086
2023
Q4 		$347 Sell
12
-56
-82% -$1.49K ﹤0.01% 3107
2023
Q3 		$1.88K Buy
68
+15
+28% +$457 ﹤0.01% 2842
2023
Q2 		$1.59K Hold
53
– – ﹤0.01% 2816
2023
Q1 		$1.92K Hold
53
– – ﹤0.01% 2792
2022
Q4 		$1.89K Sell
53
-8
-13% -$278 ﹤0.01% 2704
2022
Q3 		$2K Buy
+61
New +$1.99K ﹤0.01% 2759
2020
Q4 		– Sell
-76
Closed -$2K – 2713
2020
Q3 		$2K Hold
76
– – ﹤0.01% 2348
2020
Q2 		$1K Buy
+76
New +$1.68K ﹤0.01% 2373

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallel Advisors's SUPN Position: Q1 2026 in Review

Parallel Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 78% in Q1 2026, selling an estimated $3.82K and leaving 21 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #3531.

Parallel Advisors first reported a position in SUPN in Q2 2020 and has held it in 17 quarters since. The position peaked at $4.77K in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Parallel Advisors held 21 shares of Supernus Pharmaceuticals worth $1.08K as of Q1 2026.
  • Parallel Advisors sold 75 Supernus Pharmaceuticals shares in Q1 2026, an estimated $3.82K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3531 holding.
  • Parallel Advisors first reported a position in Supernus Pharmaceuticals in Q2 2020 and has held it in 17 quarters since.
  • Parallel Advisors's Supernus Pharmaceuticals position peaked at $4.77K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.